3
ICAP

United States

United States

ICAP’s two research centers in New York, the Bronx Prevention Center and the Harlem Prevention Center, are hubs of research in New York City that have been historically underserved and disproportionately impacted by the HIV epidemic and, more recently, the COVID-19 epidemic. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of and engagement with the research studies.

Led by Wafaa El-Sadr, MD, MPH, MPA and Jessica Justman, MD, this work is supported through the ICAP at Columbia University Clinical Trials Unit (CTU). The ICAP CTU aims to support the design and implementation of research to address gaps in the global HIV response, including through clinical research sites in the Harlem, Bronx, and Eswatini.

The Community Advisory Board (CAB) for the ICAP Clinical Trials Unit (CTU) provides guidance and feedback on proposed studies, outreach strategies, feedback on study materials, and information regarding community perceptions of the potential or current research studies.

Current studies include investigations of antibody-mediated prevention using broadly neutralizing antibodies (bnAbs) to prevent HIV or COVID-19, an injectable long-acting pre-exposure prophylaxis (PrEP) option, mobile technologies to improve PrEP adherence, integrated care for people who inject opiates, HIV vaccine studies, and studies of COVID-19 immunity, vaccine efficacy, and treatment among others.

Through Columbia University, ICAP also supports additional COVID-19 surveys and various student fellowship programs, engaging students to participate in the design, implementation, and evaluation of ICAP-supported programs while working side-by-side with its experts.

Columbia Univesity
Mailman School of Public Health

Current Studies

The LEXICON StudyDistricts (or national):New York City

Completed Studies

The SILVER StudyDistricts (or national):New York City

Harlem Prevention Center

Current HPC Studies

CoVPN 3003 -The ENSEMBLE StudyDistricts (or national):Harlem

CoVPN 3006Districts (or national):Harlem

CoVPN 3502 The HEROIC StudyDistricts (or national):Harlem

CoVPN 5002: The COMPASS StudyDistricts (or national):Harlem

HPTN 091: I AM StudyDistricts (or national):Harlem

HTPN 083: Give PrEP a ShotDistricts (or national):Harlem

HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Harlem

HVTN 706 - The MOSAICO StudyDistricts (or national):Harlem

HVTN130/HPTN089Districts (or national):Harlem

HVTN405/HPTN1901: HIV Vaccine Trials NetworkDistricts (or national):Harlem

Completed HPC Studies

HPTN 067: Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking (The ADAPT Study)Districts (or national):Harlem

PrEPared & Strong - Clinic-based PrEP for Black MSMDistricts (or national):Harlem

The STAR Study-Seek, Test, and Retain: Linkages for Black HIV+, Substance-Using MSMDistricts (or national):Harlem

Bronx Prevention Center

Current BPC Studies

ACTIV-2/A5401: The ACTIV StudyDistricts (or national):Bronx

CoVPN 3002: The AstraZeneca StudyDistricts (or national):Bronx

CoVPN 5002: The COMPASS StudyDistricts (or national):Bronx

EVOGUARD/EVO100-311: The ICON StudyDistricts (or national):Bronx

HPTN 094: The INTEGRA StudyDistricts (or national):Bronx

HTPN 083: Give PrEP a ShotDistricts (or national):Bronx

HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Bronx

IMPOWER-022: The Merck StudyDistricts (or national):Bronx

Completed BPC Studies

HPTN 076: Phase II Safety and Acceptability of Injectible Rilpivirine for PrEPDistricts (or national):Bronx

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal ProductsDistricts (or national):Bronx

MTN-014: Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% GelDistricts (or national):Bronx

ICAP in the United States

Program Start

2004

Key Technical Areas
  • Clinical Research and Trials

  • COVID-19 Research

  • PrEP Research
  • Surveys
  • Sexually Transmitted Infections Research
Current Funders
  • The Rockefeller Foundation
  • The Samuels Foundation
  • The New York Community Trust

 

 

ICAP Founder and Global Director

Dr. Wafaa El-Sadr, MD, MPH, MPA

Dr. Wafaa El-Sadr is the founder and director of ICAP and an international expert in epidemiology and research on the prevention and management of HIV, tuberculosis, and other infectious diseases. She is also the director of Columbia World Projects. For over three decades, she has advocated for families and communities most impacted by HIV and championed a collaborative, multidisciplinary approach to confronting the global epidemic.

Based at Columbia University, she leads ICAP’s portfolio of projects in 30 countries and manages a global team of over 2,000 staff. Under her leadership, ICAP has become a global leader in HIV and health systems strengthening. She is also the director of the Mailman School’s Global Health Initiative (GHI), which mobilizes the University community to address critical challenges in global health.

Read More

 

Jobs in the United States

For international ICAP job listings see careers at ICAPACITY